TherapeuticsMD, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
TherapeuticsMD, Inc. (TXMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 9.00 thousand shares for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2024-08-12
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-12-31 was 8.00K shares, a 63.64% decline year-over-year.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-09-30 was 2.00K shares, a 96.67% decline year-over-year.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-06-30 was 21.00K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-03-31 was 69.00K shares.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 100.00K shares, a 43.50% decline from fiscal 2022.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 177.00K shares, a 742.86% increase from fiscal 2021.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2021 was 21.00K shares, a 94.57% decline from fiscal 2020.
- TherapeuticsMD, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 387.00K shares, a 1388.46% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month as first filed |
|---|---|---|---|---|---|
| 2024-06-30 | 9.00K shares 10-Q · filed 2024-08-12 | ||||
| 2023-12-31 | 8.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 10.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 31.00K shares derived: sum of 3 quarters · filed 2024-03-29 | 100.00K shares 10-K · filed 2024-03-29 | |
| 2023-09-30 | 2.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 23.00K shares derived: sum of 2 quarters · filed 2023-11-14 | 92.00K shares 10-Q · filed 2023-11-14 | 114.00K shares derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-06-30 | 21.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 90.00K shares 10-Q · filed 2023-08-14 | 112.00K shares derived: sum of 3 quarters · filed 2024-03-29 | 172.00K shares derived: sum of 4 quarters · filed 2024-03-29 | |
| 2023-03-31 | 69.00K shares 10-Q · filed 2023-05-15 | 91.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 151.00K shares derived: sum of 3 quarters · filed 2024-03-29 | ||
| 2022-12-31 | 22.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 82.00K shares derived: sum of 2 quarters · filed 2024-03-29 | 177.00K shares 10-K · filed 2024-03-29 | ||
| 2022-09-30 | 60.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 155.00K shares 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | 95.00K shares 10-Q · filed 2022-08-15 | ||||
| 2021-12-31 | -462.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-07 | -102.00K shares derived: sum of 2 quarters · filed 2023-04-07 | 21.00K shares 10-K · filed 2023-04-07 | 1.03M shares 10-K · filed 2022-03-23 | |
| 2021-09-30 | 360.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 483.00K shares 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | 123.00K shares 10-Q · filed 2021-08-04 | ||||
| 2020-12-31 | 387.00K shares 10-K · filed 2022-03-23 | 386.61K shares 10-K · filed 2021-03-04 | |||
| 2019-12-31 | 26.00K shares 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |